Lung Cancer

Tedopi, a novel lung cancer vaccine, demonstrated improved survival and safety profile, according to preliminary findings from a phase 3 trial.

The treatment combination of Imfinzi plus radiotherapy is “promising” for certain patients with NSCLC, according to preliminary findings from a trial.

Treatment with perioperative Imfinzi plus neoadjuvant chemotherapy may improve surgery outcomes for patients with resectable non-small cell lung cancer.

As The Los Angeles Rams celebrate a cancer survivor and a 9/11 survivor reveals his fourth cancer diagnosis, this is what’s happening in the oncology space this week.

Adding Imfinzi the pre- and post-surgical treatment for patients with non-small cell lung cancer led to improved results, research showed.

The three-drug combination of Tagrisso plus platinum-based chemotherapy and pemetrexed boosted outcomes for patients with EGFR-mutant advanced non-small cell lung cancer.

Data revealed promising results for the combination of Trodelvy and Keytruda as a first-line treatment for patients with metastatic non-small cell lung cancer.

The TROPION-Lung04 trial reveals improvements from combining Dato-DXd with Imfinzi with or without carboplatin for patients with previously untreated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations.

The phase 2 ARROS-1 trial will investigate NVL-520 in patients with pretreated ROS1-positive non-small cell lung cancer or other solid tumors.

The phase 3 MARIPOSA- 2 study shows significant improvement within progression free survival after implementing Rybrevant into treatment for patients with non-small cell lung cancer.

For three-and-a-half years, my cancer was stable.

Patients treated with 12 months of Lixiana, an anticoagulant therapy, received a greater benefit than those treated with three months of the therapy.

The addition of Tumor Treating Fields to standard therapy tended to improve overall survival in patients with pretreated metastatic non-small cell lung cancer.

The use of Gavreto is shown to be effective and very well-tolerated in patients with metastatic RET fusion-positive NSCLC, according to an expert.

When asked for recommended treatments for certain types of cancer, ChatGPT missed the mark about one-third of the time, research showed.

Someone was watching over me the day I was diagnosed with non-small cell lung cancer.

The Oncologic Drug Advisory Committee will review data to determine if Lumakras should gain FDA approval for certain patients with KRAS G12C-mutant non-small cell lung cancer.

Chemoimmunotherapy was tested in patients with extensive-stage small cell lung cancer to determine its effect based on different performance statuses.

I am a big believer in the proverbial toolbox.

The members of my lung cancer support group recently came up with some responses for when people ask us, "So you have lung cancer — did you smoke?"

Don’t waste your cancer.

This regular approval provides Gavreto as a treatment option for patients with metastatic RET fusion-positive non-small cell lung cancer.

Tecentriq, compared with chemotherapy, improved survival while maintaining quality-of-life in patients with non-small cell lung cancer considered ineligible for platinum-based chemotherapy.

Researchers conducting this trial will compare zipalertinib plus chemotherapy with chemotherapy alone in patients with previously untreated, locally advanced or metastatic non-small cell lung cancer with the EGFR exon 20 insertion mutation.

Patients with non-small cell lung cancer who recently received surgery are more susceptible to wildfire smoke exposure, worsening their overall survival rate.

After being diagnosed with lung cancer, I found a group of patients with a similar diagnosis to me. Together, we protect each other like the clown fish and anemone at the bottom of the sea.

The treatment combination of Rybrevant and chemotherapy significantly improved progression-free survival rates for patients newly diagnosed with metastatic NSCLC with EGFR Exon 20 insertion mutations.

A randomized clinical trial, CHEERS, determined that the combination of stereotactic body radiotherapy (SBRT) and immune checkpoint inhibitors (ICIs) were ineffective as treatment for patients with advanced solid tumors.

I think it was Theodore Geisel (aka Dr Seuss) who said “Don’t cry because it’s over, smile because it happened.”

A blood test protocol proved to be more effective than US Preventative Services Task Force criteria for predicting which patients are at a higher risk of dying from lung cancer.